CM
ENZ

Crestline Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Crestline Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-49,999
Closed -$254K – 210
2016
Q3 		$254K Buy
+49,999
New +$299K 0.03% 174

Other funds holding ENZ

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Crestline Management's ENZ Position: Q4 2016 in Review

Crestline Management sold out of Enzo Biochem, Inc. (ENZ) in Q4 2016, closing a stake of 49,999 shares — an estimated $254K sold.

Crestline Management first reported a position in ENZ in Q3 2016 and held it in 1 quarter. The position peaked at $254K in Q3 2016. 109 funds tracked by Wall St. Rank hold ENZ as of Q4 2016.

  • Crestline Management reported no remaining Enzo Biochem, Inc. position as of Q4 2016 after selling out during the quarter.
  • Crestline Management sold 49,999 Enzo Biochem, Inc. shares in Q4 2016, an estimated $254K.
  • Crestline Management first reported a position in Enzo Biochem, Inc. in Q3 2016 and held it in 1 quarter.
  • Crestline Management's Enzo Biochem, Inc. position peaked at $254K in Q3 2016.
  • 109 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2016.

Based on Crestline Management's 13F filing for Q4 2016, filed 14 Feb 2017.